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Dear Editor,
Determining hepatitis B virus (HBV) genotypes in a clin-
ical setting not only aids therapeutic strategies but also 
expands the current knowledge of HBV molecular epi-
demiology. Recently many molecular approaches have 
been developed to differentiate different worldwide HBV 
genotypes, each approach with its own pros and cons. To 
establish such a critical method, several important con-
cerns should be regarded (1, 2). Therefore, prior to releas-
ing a molecular diagnostic approach and suggesting its 
usage for large-scale clinical and epidemiological stud-
ies, it is necessary to determine and verify the accuracy of 
the assay. We read with great interest the article written 
by Farazmandfar et al. regarding distinguishing HBV gen-
otypes using type-specific primers, which is published by 
the “Journal of Virological Methods” (3). The advantage of 
the method is that it can detect all eight HBV genotypes 
(A-H) in comparison to the similar method that was intro-
duced before and was unable to detect HBV genotypes H 
and F (4).  To report a novel assay, all procedures should be 
defined precisely for other researchers. One of the main 
concerns of a novel molecular diagnostic method is to 
ensure that the method is optimized and validated with 
proper and standard controls. In the current study, the 
nature of samples and/or controls is unclear although 
the authors declared HBV DNA positive controls and/or 
positive serum samples in their study. It is uncertain that 
how the method was set up and optimized. If the method 
was optimized based on clinical samples, the reference 
controls used to validate the system are unclear. If the 
method was optimized based on previously defined ref-
erence HBV DNA controls (i.e. plasmids that carry out dif-
ferent HBV genotypes), there is no report on the clinical 
validation of the assay. Obtaining amplification signals 
using reference controls would be achieved readily. Thus, 
there is a flaw in details of assay optimization and vali-
dation in the introduced molecular method; specifically, 
sample and/or reference control collection and prepara-
tion, nucleic acid extraction and negative/positive con-
trols were not addressed clearly in this study. 
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specificity, as well as positive and negative predictive 
value are other important concerns about the molecular 
diagnostic assay. Although the sensitivity of the method 
was reported to be 100-200 copies/mL of blood, the calcu-
lation method was not mentioned. It would make sense 
that the authors have used HBV vectors to determine 
the copy number of each genotype, but it is ambiguous 
that how this value has been calibrated and then gener-
alized to blood samples. Moreover, there isn’t any report 
regarding patients’ samples and method of blood HBV 
DNA extraction. Analytical specificity could be shown by 
mixture of non-matched HBV DNA genotypes and prim-
ers in a same PCR reaction.  It is worth noting that  most 
of the similar methods utilize nested PCR approach to 
increase the sensitivity of the assay for clinical samples. 
Since the method was not clinically validated based on 
clinical samples, there is no warranty that the method 
would be sensitive enough to detect HBV DNA after blood 
extraction. Consequently, there is no data about posi-
tive and negative predictive values based on population 
study. Once more, this question comes up that if the au-
thors optimized their method based on clinical samples 
obtained from the Mazandaran University of Medical Sci-
ences, which type of reference controls were employed 
to validate their method. The authors checked out per-
formance of the assay and showed the accurate intra-run 
precision of the method by running a triplicate experi-
ment, but this was not tested on clinical samples. Thus, 
clinical validation of the assay remains to be established 
as well.
Altogether, when a new molecular diagnostic method is 
developed, informative methodological references that 
were used during the optimization and validation pro-
cess such as analytical sensitivity, specificity, precision, 
accuracy, and clinical validity should be provided. This 
would give other researchers confidence in the validity of 
the techniques, which will encourage future use of such 
a novel method.
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